Pfizer (NYSE: PFE) will report its fourth-quarter results on Feb. 8 and investors are bound to find answers to questions about the company's ongoing performance. Aside from the usual slew of clinical trial updates and new pipeline projects, all eyes will be on sales of Comirnaty and Paxlovid, the pharma company's two commercialized coronavirus medicines. Let's take a moment to consider the most relevant factors for investors as they make buying or selling decisions when the earnings report is published next month.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting